Overview of conjugation strategies for making ISACs (immune-stimulating antibody conjugates). InvivoGen offers conjugatable PRR ligands that are chemically modified to allow their attachment to a peptide/protein of interest (POI) with a chemical linker.

COVID-19 is a pandemic that threatens global health. Its causative agent, SARS-CoV-2, a novel β-coronavirus, binds to ACE2 expressed on host cells and once inside it hijacks host machinery to transcribe, replicate and translate its RNA genome. The resulting pro-inflammatory response is enhanced, unbalanced, and devastating.

Learn more about the growing evidence that re-infection by SARS-CoV-2 can occur, with protective immunity either not strong enough, or not long-lasting in all individuals.

The global vaccine effort in response to the COVID-19 pandemic is unprecedented in terms of both scale and speed. SARS-CoV-2 vaccines will be essential in reducing mortality when the virus establishes itself in the population. The race is now on for the development of both a safe and, effective vaccine against SARS-CoV-2.

Currently, there is very limited knowledge of the host immune response to SARS-CoV-2. However, based on the clinical and experimental data on SARS-CoV and MERS-CoV predictions can be made on how the host immune system will respond and possibly viral evasion strategies.

Review explaining how to avoid unwanted anti-therapeutic antibody responses in mice and bias in data interpretation before moving to clinical trials in humans.

In this first newsletter of 2023, InvivoGen highlights the current knowledge about the NLRP1 and NLRP3 inflammasome sensors and discusses the experimental difficulty in assessing their respective role in pathophysiological contexts.

InvivoGen presents a new Insight Newsletter reviewing TLR7 and TLR8 reporter cells, designed to monitor the intertwined NF-κB and IRF responses of the two Toll-Like Receptors TLR7 and TLR8. Also, M5049 (aka Enpatoran), a novel TLR7- and TLR8-specific antagonist, was added to our growing library of TLR7/8 ligands.

Adjuvants are essential for enhancing and directing the adaptative immune response to vaccine antigens. This response is mediated by two main types of lymphocytes, B and T cells.

InvivoGen has developed a simple assay to study Spike-ACE2-dependent cell fusion

SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), the causative agent of COVID-19, was first reported in Wuhan (China) and has rapidly disseminated around the globe.

InvivoGen has designed the pNiFty plasmid collection to help develop exclusive Dual™ reporter cell lines that fit your research.

InvivoGen offers a collection of biological tools to assess two key functions of the SARS-CoV-2 Spike protein: infection of target cells and cell fusion.

Spike (S) is a structural glycoprotein expressed at the SARS-CoV-2 (2019-nCoV) surface and is a critical determinant of the viral host and tissue tropism.

InvivoGen's anti-CoV2RBD monoclonal antibodies (mAbs) have been tested in-house to compare their activity.

Regulated cell death (RCD) is a lethal process taking place in the context of stressful stimuli (e.g. infections, metabolic disorders, or genotoxic agents) for which no restoration of cellular homeostasis could be completed.

The Nucleocapsid (N) is a structural protein playing a key role in the SARS-CoV-2 (2019-nCoV) life cycle, including replication, transcription, and genome packaging. 

A concise review about our current knowlegde of the Stimulator of Interferon Gens (STING) protein. Learn about STING activity, STING agonists and signaling inhibitors, STING regulation, genetic variation of STING, and therapeutic targeting of STING.

NLRP3 is the best-described inflammasome sensor and an attractive drug target.